Method of treatment with coadministration of aspirin and prasugrel

A method for treating a disease caused by thrombus or embolus, said method consisting of separately administering to a human in need of reduction of thrombogenesis or reduction of platelet aggregation:

• (a) 2-acetoxy-5 -(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and
• (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents,
• wherein said 2-acetoxy-5 -(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to treat said disease caused by thrombus or embolus by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

A method for treating a patient undergoing stenting or angioplasty consisting of separately administering to said patient:

• (a) 2-acetoxy-5 -(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3 ,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and
• (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents,
• wherein said 2-acetoxy-5 -(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to reduce the incidence or severity of restenosis in said patient undergoing stenting or angioplasty, after both (a) and (b) have been administered.

A method for reducing event rate of diseases caused by thrombus or embolus, said method consisting of separately administering to a human in need of reduction of said event rate of said diseases:

• (a) 2-acetoxy-5 -(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3 ,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and
• (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents,
• wherein said 2-acetoxy-5 -(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to said reduce event rate of said diseases caused by thrombus or embolus by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

A method for reducing thrombotic cardiovascular or thrombotic cerebrovascular events in a human in need of reduction of said events, said method consisting of separately administering:

• (a) 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and
• (b) aspirin, one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents,
• wherein said 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to reduce thrombotic cardiovascular or thrombotic cerebrovascular events by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

A method for reducing thrombogenesis or reducing platelet aggregation in a human, said method consisting of separately administering to said human:

• (a) 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3 ,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and
• (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents,
• wherein said 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to reduce thrombogenesis or reduce platelet aggregation in said human, after both (a) and (b) have been administered.